Press Releases

Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit

~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~

SAN DIEGO, CA / ACCESSWIRE / October 11, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that Dr. William Schmidt, Chief Medical Officer of Ensysce, will serve as Chairperson of the 17^th Annual Pain Therapeutics Summit taking place on October 19 and 20, 2023 in San Diego, CA.

Dr. Schmidt's extensive career and distinct expertise in leading clinical studies of novel pain management drugs provides a strong foundation to Chair the summit on Thursday, October 19, 2023.

The 17^th Annual Pain Therapeutics Summit

San Diego, CA, October 19-20, 2023

The Annual Pain Therapeutics Summit has the objective to identify and advance novel pain drugs through preclinical, clinical development and commercialization. It brings leaders together from the fields of advanced medicine and science, academia and government. This year's event will highlight novel therapeutics in the field of pain and novel trends in pain management, as well as panel discussions on key issues facing pain research today. The event is a prominent gathering of experts dedicated to improving the lives of those suffering from chronic pain. Please find more information here.

Dr. Schmidt, Chief Medical Officer, Ensysce Biosciences, has spent his career developing novel products to treat pain and most recently has specialized in working with companies developing highly novel analgesics. Dr. Schmidt is the Parliamentarian and a Past President of the Eastern Pain Association. He received the John J. Bonica award for the development of new analgesics and his sustained contributions to the educational efforts of the Eastern Pain Association in 2014. Dr. Schmidt currently sits on the Scientific or Medical Advisory Boards of three biotech companies and one internet medical publishing company.

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP^TM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from its fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact:

Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:

Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us

SOURCE: Ensysce Biosciences Inc.

Released October 11, 2023